Chang_2022_J.Formos.Med.Assoc__

Reference

Title : Sugammadex reversal of muscle relaxant blockade provided less Post-Anesthesia Care Unit adverse effects than neostigmine\/glycopyrrolate - Chang_2022_J.Formos.Med.Assoc__
Author(s) : Chang HC , Liu SY , Lee MJ , Lee SO , Wong CS
Ref : J Formos Med Assoc , : , 2022
Abstract :

Sugammadex is a direct reversal agent of aminosteroid muscle relaxants, particularly rocuronium, with promptly and completely reverse of deep neuromuscular block (NMB), which allows better surgical conditions. Sugammadex exhibits advantages over indirect reversal agent acetylcholinesterase inhibitor neostigmine with less adverse effects. In this retrospective review, we compared the incidence of postoperative vomiting (POV), postoperative urinary retention (POUR), and hemodynamic changes between sugammadex and neostigmine/glycopyrrolate in reversal of muscular blockade. Sugammadex showed superior in all three aspects. The heart rate was 7.253 lower (P < 0.0001) and mean arterial pressure was 5.213 lower (P < 0.0001) in sugammadex group. The POV of neostigmine/glycopyrrolate group was 3.16 times more than sugammadex group (OR = 3.16, p < 0.0001), and POUR of neostigmine/glycopyrrolate group was 4.291 times more than sugammadex group (OR = 4.291, p < 0.0001). Sugammadex showed better hemodynamic stability, and lower incidence of POV and POUR than neostigmine/glycopyrrolate.

PubMedSearch : Chang_2022_J.Formos.Med.Assoc__
PubMedID: 35577643

Related information

Chemical Sugammadex

Citations formats

Chang HC, Liu SY, Lee MJ, Lee SO, Wong CS (2022)
Sugammadex reversal of muscle relaxant blockade provided less Post-Anesthesia Care Unit adverse effects than neostigmine\/glycopyrrolate
J Formos Med Assoc :

Chang HC, Liu SY, Lee MJ, Lee SO, Wong CS (2022)
J Formos Med Assoc :